Indolent Behavior of Malignant Bethesda III Nodules Compared to Bethesda V/VI Nodules
The Journal of Clinical Endocrinology & Metabolism · 2024
DOI: 10.1210/clinem/dgae108 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2024. Verfasst von Mayumi Endo und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology, Diabetes, and Metabolism, The Ohio State University and Arthur G. James Cancer Center, Columbus, OH 43210, USA. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Thyroid Nodule. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Ohio State University Comprehensive Cancer Center, NIH.
Abstract (Originalsprache)
Background
The Bethesda system classifies all fine-needle aspiration specimens into 1 of 6 categories. We speculated that cancers within each Bethesda category would have distinct clinical behavior.
Methods
This is a retrospective analysis of patients from a single academic medical center with a histologic diagnosis of thyroid cancer who had an initial diagnosis of Bethesda III, IV, V, or VI cytology.
Results
A total of 556 cases were included, with 87 cases of Bethesda III, 109 cases of IV, 120 cases of V, and 240 cases of VI. Bethesda III showed similarities with V/VI compared to IV with a predominance of papillary thyroid cancer. The interval from diagnosis to surgery was longer in Bethesda III compared to Bethesda V/VI (median 78 vs 41 days, P < .001) (Fig. 1). Yet, patients with Bethesda III had a higher probability of achieving remission (62% vs 46%, P < .03), a lower possibility of recurrence (8% vs 24%, P < .001), and a shorter interval to achieve remission (median 1218 vs 1682 days, P = .02) compared to Bethesda V/VI, which did not change after adjusting for age, sex, radioactive iodine therapy, mode of surgery, and tumor size. More than 70% of Bethesda III that later presented with recurrence had T3/T4 disease or distant metastasis.
Conclusion
Cancers with Bethesda III cytology had a less aggressive clinical phenotype with better prognosis compared to V/VI despite histological similarities. The time to remission was shorter in Bethesda III despite a longer interval between diagnosis and surgery. The initial cytological diagnosis may guide management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Endocrinology, Diabetes, and Metabolism, The Ohio State University and Arthur G. James Cancer Center, Columbus, OH 43210, USA.
- Division of Metabolism, Endocrinology, and Nutrition, University of Washington, Seattle, WA 98195, USA.
- Division of Human Genetics, The Ohio State University and Arthur G. James Cancer Center, Columbus, OH 43210, USA.
- Center for Biostatistics and Bioinformatics, The Ohio State University, Columbus, OH 43210, USA.
- Department of Internal Medicine, New York University Langone Health, New York, NY 10016, USA.
ORCID-Profile: Mayumi Endo, Irina Azaryan, Jennifer A Sipos
Förderung
- NCI NIH HHS
- Ohio State University Comprehensive Cancer Center
- NIH
Zitieren
APA
Endo, M., Peng, J., Nabhan, F. A., Brock, P., Azaryan, I., Long, C., Ryan, L. E., Ringel, M. D., & Sipos, J. A. (2024). Indolent Behavior of Malignant Bethesda III Nodules Compared to Bethesda V/VI Nodules. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgae108
Vancouver
Endo M, Peng J, Nabhan FA, Brock P, Azaryan I, Long C, et al. Indolent Behavior of Malignant Bethesda III Nodules Compared to Bethesda V/VI Nodules. The Journal of Clinical Endocrinology & Metabolism. 2024. doi:10.1210/clinem/dgae108
BibTeX
@article{Endo2024,
author = {Endo, Mayumi and Peng, Jing and Nabhan, Fadi A and Brock, Pamela and Azaryan, Irina and Long, Clarine and Ryan, Laura E and Ringel, Matthew D and Sipos, Jennifer A},
title = {Indolent Behavior of Malignant Bethesda III Nodules Compared to Bethesda V/VI Nodules},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2024},
doi = {10.1210/clinem/dgae108}
}
EUVIMED